Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:CYTK NASDAQ:KRYS NASDAQ:LENZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$24.84-2.2%$23.82$13.40▼$26.65$4.28B0.751.90 million shs2.81 million shsCYTKCytokinetics$51.50-1.1%$38.36$29.31▼$59.39$6.23B0.622.65 million shs1.98 million shsKRYSKrystal Biotech$141.21-2.7%$146.85$122.80▼$207.84$4.20B0.66255,319 shs310,516 shsLENZLENZ Therapeutics$39.89+0.7%$35.34$16.53▼$42.77$1.13B0.45531,607 shs192,700 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+0.51%-2.31%+3.21%+14.37%+58.00%CYTKCytokinetics-1.74%+47.44%+52.71%+50.81%-3.70%KRYSKrystal Biotech-3.37%-1.69%+4.72%+5.06%-21.17%LENZLENZ Therapeutics-5.60%+2.59%+14.27%+41.13%+66.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$24.84-2.2%$23.82$13.40▼$26.65$4.28B0.751.90 million shs2.81 million shsCYTKCytokinetics$51.50-1.1%$38.36$29.31▼$59.39$6.23B0.622.65 million shs1.98 million shsKRYSKrystal Biotech$141.21-2.7%$146.85$122.80▼$207.84$4.20B0.66255,319 shs310,516 shsLENZLENZ Therapeutics$39.89+0.7%$35.34$16.53▼$42.77$1.13B0.45531,607 shs192,700 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+0.51%-2.31%+3.21%+14.37%+58.00%CYTKCytokinetics-1.74%+47.44%+52.71%+50.81%-3.70%KRYSKrystal Biotech-3.37%-1.69%+4.72%+5.06%-21.17%LENZLENZ Therapeutics-5.60%+2.59%+14.27%+41.13%+66.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.61Moderate Buy$29.0617.00% UpsideCYTKCytokinetics 2.87Moderate Buy$75.3846.38% UpsideKRYSKrystal Biotech 2.88Moderate Buy$210.3848.98% UpsideLENZLENZ Therapeutics 3.00Buy$49.6024.34% UpsideCurrent Analyst Ratings BreakdownLatest LENZ, ACAD, KRYS, and CYTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025ACADACADIA PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$36.00 ➝ $39.009/3/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $71.009/3/2025CYTKCytokineticsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$60.00 ➝ $80.009/2/2025CYTKCytokineticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/2/2025CYTKCytokineticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$77.00 ➝ $84.009/2/2025CYTKCytokineticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$87.00 ➝ $96.009/2/2025CYTKCytokineticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$78.009/2/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$72.008/22/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$219.00 ➝ $216.008/22/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$240.008/8/2025ACADACADIA PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $36.00(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$957.80M4.38$0.69 per share36.02$4.40 per share5.65CYTKCytokinetics$18.47M333.65N/AN/A($1.15) per share-44.78KRYSKrystal Biotech$290.52M14.07$4.51 per share31.31$32.90 per share4.29LENZLENZ TherapeuticsN/AN/AN/AN/A$7.42 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$226.45M$1.3318.6832.686.4321.80%14.69%9.41%11/5/2025 (Estimated)CYTKCytokinetics-$589.53M-$5.100.00N/AN/A-707.17%N/A-45.52%11/5/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.9229.5114.01N/A40.85%15.21%13.81%11/3/2025 (Estimated)LENZLENZ Therapeutics-$49.77M-$1.900.00N/AN/AN/A-25.63%-24.43%11/5/2025 (Estimated)Latest LENZ, ACAD, KRYS, and CYTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CYTKCytokinetics-$1.34-$1.12+$0.22-$1.12$1.95 million$66.77 million8/6/2025Q2 2025ACADACADIA Pharmaceuticals$0.14$0.16+$0.02$0.16$263.07 million$264.57 million8/4/2025Q2 2025KRYSKrystal Biotech$1.08$1.29+$0.21$1.29$95.42 million$96.04 million7/30/2025Q2 2025LENZLENZ Therapeutics-$0.58-$0.53+$0.05-$0.53$5.00 million$5.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.912.83CYTKCytokineticsN/A6.766.76KRYSKrystal BiotechN/A9.689.33LENZLENZ TherapeuticsN/A20.5420.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%CYTKCytokineticsN/AKRYSKrystal Biotech86.29%LENZLENZ Therapeutics54.32%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals28.30%CYTKCytokinetics3.40%KRYSKrystal Biotech13.70%LENZLENZ Therapeutics6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510168.71 million120.97 millionOptionableCYTKCytokinetics250119.66 million115.59 millionOptionableKRYSKrystal Biotech21028.94 million24.98 millionOptionableLENZLENZ Therapeutics11028.52 million26.55 millionN/ALENZ, ACAD, KRYS, and CYTK HeadlinesRecent News About These Companies537,738 Shares in LENZ Therapeutics, Inc. $LENZ Acquired by Adage Capital Partners GP L.L.C.September 8 at 4:57 AM | marketbeat.comGranahan Investment Management LLC Acquires 124,324 Shares of LENZ Therapeutics, Inc. $LENZSeptember 7 at 6:20 AM | marketbeat.comLENZ Therapeutics, Inc. (LENZ) Therapeutics, Inc. Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.comScoggin Management LP Purchases Shares of 100,000 LENZ Therapeutics, Inc. $LENZSeptember 3, 2025 | marketbeat.comParadigm Biocapital Advisors LP Boosts Holdings in LENZ Therapeutics, Inc. $LENZSeptember 2, 2025 | marketbeat.comAlphaQuest LLC Buys New Position in LENZ Therapeutics, Inc. $LENZSeptember 2, 2025 | marketbeat.comNuveen LLC Invests $1.72 Million in LENZ Therapeutics, Inc. $LENZSeptember 1, 2025 | marketbeat.comLENZ Therapeutics, Inc. $LENZ Shares Acquired by Vanguard Group Inc.August 30, 2025 | marketbeat.comLENZ Therapeutics: Adjusting My Position After Almost Doubling In Four MonthsAugust 28, 2025 | seekingalpha.comLENZ Therapeutics (NASDAQ:LENZ) Sees Strong Trading Volume - Here's What HappenedAugust 27, 2025 | marketbeat.comFDA Approves Eye Drops That Fix Near Vision Without GlassesAugust 25, 2025 | yahoo.comLENZ Therapeutics to Present at Upcoming Investor and Medical ConferencesAugust 25, 2025 | markets.businessinsider.comWill FDA Approval of Vizz Eye Drops Change LENZ Therapeutics' (LENZ) Narrative?August 21, 2025 | finance.yahoo.comThe emerging era of presbyopia-correcting eye drops: What’s next?August 20, 2025 | ophthalmologytimes.comONew FDA approved eye drops for vision is coming soonAugust 19, 2025 | msn.comLord Abbett & CO. LLC Makes New Investment in LENZ Therapeutics, Inc. (NASDAQ:LENZ)August 19, 2025 | marketbeat.comNo Need For Reading Glasses? Vizz Eye Drop That Improves Near Vision Has FDA NodAugust 18, 2025 | msn.comLENZ Therapeutics (NASDAQ:LENZ) Sees Unusually-High Trading Volume - Time to Buy?August 17, 2025 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of "Buy" by BrokeragesAugust 16, 2025 | marketbeat.comFDA approves aceclidine eye drops for the treatment of presbyopiaAugust 15, 2025 | aop.org.ukAFDA Approves Vizz, First Daily Eye Drop For Age-Related Blurry VisionAugust 15, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLENZ, ACAD, KRYS, and CYTK Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$24.84 -0.55 (-2.17%) Closing price 04:00 PM EasternExtended Trading$24.78 -0.07 (-0.26%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Cytokinetics NASDAQ:CYTK$51.50 -0.59 (-1.13%) Closing price 04:00 PM EasternExtended Trading$50.71 -0.79 (-1.53%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Krystal Biotech NASDAQ:KRYS$141.21 -3.99 (-2.75%) Closing price 04:00 PM EasternExtended Trading$141.17 -0.04 (-0.03%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.LENZ Therapeutics NASDAQ:LENZ$39.89 +0.26 (+0.66%) Closing price 04:00 PM EasternExtended Trading$40.33 +0.44 (+1.10%) As of 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
